Original Article
Brief Report
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
N Engl J Med 2005; 353:2667-2672December 22, 2005
- Abstract
Influenza A (H5N1) virus with an amino acid substitution in neuraminidase conferring high-level resistance to oseltamivir was isolated from two of eight Vietnamese patients during oseltamivir treatment. Both patients died of influenza A (H5N1) virus infection, despite early initiation of treatment in one patient. Surviving patients had rapid declines in the viral load to undetectable levels during treatment. These observations suggest that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated with clinical deterioration and that the strategy for the treatment of influenza A (H5N1) virus infection should include additional antiviral agents.
Media in This Article
Figure 1
Serial Chest Radiographs Obtained from Patient 1.Figure 2
Sequencing Trace of the Neuraminidase Gene of Influenza A (H5N1) Virus Isolated from Patient 1 on the Fourth Day of Oseltamivir Treatment.Article Activity
- Article
Influenza A (H5N1) virus causes severe disease in humans and poses an unprecedented pandemic threat.1-3 The neuraminidase inhibitor oseltamivir constitutes an important treatment option, and stockpiling of this drug is part of pandemic-preparedness plans.4 However, data on the efficacy and development of drug resistance in human influenza A (H5N1) virus are scarce. We report the isolation of oseltamivir-resistant influenza A (H5N1) variants from two patients who died of the infection, in one case despite the early initiation of treatment. Furthermore, we provide evidence suggesting that the presence of detectable virus after the completion of treatment is associated with a poor outcome. These observations have implications for the treatment of influenza A (H5N1) virus infection.
Case Report
A previously healthy 13-year-old Vietnamese girl weighing 28 kg (Patient 1 in Table 1Table 1
Patients' Characteristics and Clinical and Virologic Outcome.) presented to a hospital in Dong Thap Province on January 22, 2005, with a one-day history of fever and cough. The day before, her mother (Patient 2 in Table 1) had died of influenza A (H5N1) virus infection after one day of oseltamivir treatment. Virus isolated from the mother did not reveal oseltamivir-resistance mutations. Because influenza A (H5N1) virus infection was suspected in the child at presentation, she received an initial 75-mg dose of oseltamivir and was transferred to a pediatric referral hospital. On admission, she had a temperature of 40.3°C, a pulse of 106 beats per minute, a respiratory rate of 36 breaths per minute, and normal blood pressure. Results of physical examination and routine biochemical measurements were unremarkable. Hematologic measurements showed a white-cell count of 4800 cells per cubic millimeter (normal range, 5500 to 15,500), with 12 percent lymphocytes, and a platelet count of 183,000 cells per cubic millimeter (normal range, 250,000 to 550,000). A blood culture showed no growth. A chest radiograph revealed a small focal pulmonary infiltrate in the right middle lobe (Figure 1AFigure 1Serial Chest Radiographs Obtained from Patient 1.).The patient received a second 75-mg dose of oseltamivir within 6 hours after the first, followed by a third dose within the first 24 hours after admission. Treatment was then continued for four days at the standard dose of 75 mg twice daily. Antibiotic treatment with ceftriaxone and amikacin was also given. During the first three days after admission, the patient remained in stable condition and did not require supplemental oxygen. A chest radiograph obtained on January 24 showed minimal progression of the infiltrate (Figure 1B). At that time, her white-cell count was 3100 cells per cubic millimeter, with 26 percent lymphocytes.
On January 25 (the fourth day of oseltamivir treatment), the child's respiratory condition worsened and supplemental high-dose oxygen was given, initially by nasal cannula and later by continuous positive airway pressure. Antibiotic treatment was switched to vancomycin, ciprofloxacin, and amikacin. At this time, the pneumonia involved most of the right middle zone (Figure 1C). A chest radiograph obtained on January 26 showed further progression of the infiltrate (Figure 1D). Hematologic and biochemical measurements revealed a white-cell count of 1800 cells per cubic millimeter, with 41 percent lymphocytes; a platelet count of 97,000 cells per cubic millimeter; and increased serum alanine aminotransferase and aspartate aminotransferase levels (144 and 279 U per liter, respectively; normal range, less than 55 and less than 50, respectively). Her respiratory condition continued to worsen, and she was intubated and ventilation was begun on January 27. A chest radiograph obtained on January 28 showed pneumonia involving the entire right lung and extension to the left lung (Figure 1E). She died the same day. No autopsy was performed.
Methods
Patients and Clinical Specimens
We examined sequential pharyngeal swabs from Patient 1 and seven additional patients with influenza A (H5N1) infection from whom at least one pharyngeal swab obtained before treatment and during treatment with oseltamivir was available. The swabs were collected in viral-transport medium and stored at −80°C.
Virologic Investigations
Virus isolation was performed in Madin–Darby canine-kidney cells in biosafety level III culture facilities, and influenza viruses were identified by serotype-specific reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assays and hemagglutination-inhibition assays, as described previously.2,5,6 For the diagnosis of influenza A (H5N1) infection, nucleic acids were purified from 100 μl of pharyngeal specimens and subtype-specific RT-PCR assays were performed as described previously.2,7,8 Quantitation of influenza A RNA was performed with the use of a real-time RT-PCR assay as described previously.6 The limit of detection of this assay is 1000 copies of RNA per milliliter. Quantitative analyses of serial pharyngeal specimens were performed in a batch-wise fashion. Positive and negative controls were included in all tests.
Sequence Analysis of Neuraminidase Genes
The sequence of the neuraminidase gene of initial viral isolates was analyzed as described previously,9 with the use of a BigDye Terminator Cycle Sequencing Kit (version 3.1, Applied Biosystems) on an ABI PRISM 3700 DNA Analyzer (Applied Biosystems). Sequence fragments were assembled and edited with the use of Lasergene software (version 6.0, DNASTAR). For direct sequencing of viral RNA from clinical specimens and follow-up isolates, a 200-bp fragment of N1 encompassing amino acid position 274 was amplified (primers available on request) and sequenced with the use of a CEQ Dye Terminator Cycle Sequencing Kit on a CEQ8000 system (Beckman Coulter). Alignment and residue analyses were performed with the use of BioEdit software (version 7). GenBank accession numbers of N1 sequences are shown in the Supplementary Appendix (available with the full text of this article at www.nejm.org).
Results
Isolation of Oseltamivir-Resistant influenza A (H5N1) Variants from Patient 1
Influenza A (H5N1) virus infection was diagnosed in another local laboratory by RT-PCR assay of a pharyngeal swab obtained at admission. This specimen was not available for further analysis. In our laboratory, influenza A (H5N1) virus was isolated from a throat swab obtained from Patient 1 on the fourth day of oseltamivir treatment (January 25, 2005). Sequence analysis of the neuraminidase gene revealed the substitution of tyrosine for histidine at amino acid position 274 (H274Y), associated with high-level resistance to oseltamivir in influenza (N1) viruses.10 Analysis of the raw sequencing traces revealed the presence of a minor subpopulation of wild-type 274H variants among predominating 274Y mutants (Figure 2Figure 2
Sequencing Trace of the Neuraminidase Gene of Influenza A (H5N1) Virus Isolated from Patient 1 on the Fourth Day of Oseltamivir Treatment.). Virus was also isolated from a throat specimen obtained on January 28, 2005, two days after the completion of treatment. Sequence analyses of this strain as well as of viral RNA extracted directly from the swab also revealed the H274Y change in N1. Although sequencing traces also revealed the presence of a minor wild-type 274H population in viral RNA from the swab, only 274Y variants were observed in the isolate, possibly reflecting overgrowth of the predominant mutant population during culture. Determination of influenza A (H5N1) RNA levels showed that the viral load had increased in the second specimen (Figure 3Figure 3
Influenza A (H5N1) Viral RNA Load in Throat Swabs from Eight Patients.).Virologic Responses and Isolation of a Second Oseltamivir-Resistant Strain
Of 13 patients with RT-PCR–confirmed influenza A (H5N1) infection who were admitted to the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam, between January 2004 and February 2005, at least one throat swab obtained before treatment and during treatment was available from 7 patients (Patients 2 through 8 in Table 1; additional information on clinical features at admission, treatment, and outcomes is available in the Supplementary Appendix). Treatment with oseltamivir at the recommended dose and duration (75 mg twice daily for five days, with a weight-based reduction in the dose in children less than 13 years old) was begun on the day of admission in all patients. The remaining six patients, for whom only specimens obtained at admission and not during treatment were available, presented at similar days of illness (median, six days; range, four to seven) and also began to receive oseltamivir therapy on the day of admission. Five of these patients died within one to eight days after admission (median, three).
Influenza A (H5N1) virus was isolated from throat swabs obtained at admission from six of the seven patients (Patients 2, 3, 5, 6, 7, and 8). Sequence analysis of the neuraminidase genes of these viruses revealed the wild-type 274H residue alone. Measurements of the viral RNA load in sequential throat specimens showed rapid declines to undetectable levels in four patients who survived, whereas viral RNA was still detectable at the completion of oseltamivir treatment in two patients who died (Patients 3 and 4 in Figure 3). The remaining patient died during the second day after admission, at which time an increase in the viral RNA load was observed (Patient 2 in Figure 3). Direct sequencing revealed only wild-type 274H virus in the second specimen from this patient.
All subsequent throat specimens from Patients 3 through 8 were cultured. Of these specimens, influenza A (H5N1) virus was isolated only from the last specimen from Patient 4, obtained three days after the completion of treatment (Figure 3). Sequence analysis of this isolate revealed the H274Y substitution in N1. Although sequencing traces of the isolate revealed only mutant 274Y variants, direct sequencing of viral RNA from the same swab revealed evidence of a minor subpopulation of wild-type 274H viruses similar to that in specimens from Patient 1. Patient 4 died of respiratory failure six days after the isolation of resistant virus. Direct sequences of viral RNA from swabs obtained at admission and after two days of treatment showed wild-type 274H virus alone. The limited sensitivity of the method precluded direct sequencing of further samples from this patient. Likewise, no direct sequences could be obtained from the last specimen obtained from Patient 3.
Discussion
We report the isolation from two Vietnamese patients of influenza A (H5N1) viruses with a H274Y substitution in the neuraminidase gene, which confers high-level resistance to oseltamivir.10,11 In contrast to the recent report of a partially resistant influenza A (H5N1) virus isolated during once-daily prophylactic treatment with oseltamivir,11 the viruses in our patients were isolated during or shortly after a course of oseltamivir at therapeutic twice-daily doses, and mutant 274Y variants predominated. Furthermore, although the patient with partially resistant virus ultimately received oseltamivir at therapeutic doses and survived,11 both of our patients died.
Patient 1 was treated with doses of oseltamivir that were relatively high for her weight, especially during the first day of treatment. Moreover, in this patient, unlike most patients with influenza A (H5N1) virus infection, treatment was started when the greatest clinical benefit could be expected: within 48 hours after the onset of symptoms. Indeed, her clinical condition remained stable during the first three days of treatment without the need for supplemental oxygen. However, on the fourth day of treatment she became progressively dependent on oxygen, her white-cell and platelet counts fell, and there was laboratory evidence of hepatitis. At the time of her death, the viral load in her throat had increased. These observations suggest that the development of drug resistance contributed to the failure of therapy and, ultimately, the death of this patient. In the second patient, the viral RNA load declined during treatment, but not to undetectable levels. Whereas only wild-type 274H virus was detectable after two days of treatment, 274Y mutant virus was isolated shortly after treatment. Although a direct relationship between the emergence of resistance and this patient's death was less clear, the presence of replicating virus after 14 days of illness suggests an effect on the outcome.
The emergence of resistant influenza A (H5N1) variants during oseltamivir treatment should not be surprising. In adults with influenza A (H1N1) or (H3N2) virus infection, the development of resistance to oseltamivir is rare, but resistant viral variants have been detected in up to 18 percent of children who receive oseltamivir.12-14 The difference in resistance rates between adults and children may be explained by the occurrence of a primary infection in children associated with higher rates of viral replication owing to a lack of previous immunity. Since humans have no previous immunity to influenza A (H5N1) virus, all human infections with this virus are primary infections. In addition, studies in animals indicate particularly high levels of replication of current influenza A (H5N1) strains.15,16
The efficacy of oseltamivir is unlikely to be optimal when treatment is instituted late in the course of illness, as has been the case in most patients with influenza A (H5N1) virus infection reported to date.1,2 However, antiviral treatment could still be expected to be beneficial when there is evidence of ongoing viral replication. Such benefit is suggested by the rapid decline in the viral load to undetectable levels in all four survivors in the current series. In contrast, virus was still detectable at the end of treatment in three patients who died of the infection after receiving the full course of treatment, two of whom had oseltamivir-resistant virus isolated from throat specimens. Our observations suggest that at least in some patients with influenza A (H5N1) virus infection, treatment with the recommended dose of oseltamivir incompletely suppresses viral replication. Besides allowing the infection to proceed, such incomplete suppression provides opportunities for drug resistance to develop. Multiple mechanisms may account for inadequate viral suppression by oseltamivir, including overwhelming viral replication, as suggested by the results of studies in mice15 and altered pharmacokinetics in severely ill patients, who are apt to have diarrhea.1-3 Strategies aimed at improving antiviral efficacy (e.g., the use of higher doses, longer durations of therapy, or combination therapy) may deserve further evaluation. In addition, antiviral agents to which oseltamivir-resistant influenza viruses remain susceptible should be included in treatment arsenals for influenza A (H5N1) virus infections.
Supported by the Wellcome Trust, United Kingdom.
No potential conflict of interest relevant to this article was reported.
Source Information
From the Oxford University Clinical Research Unit, Hospital for Tropical Diseases (M.D.J., T.T.T., D.Q.H., J.F.), Pediatric Hospital Number One (T.H.K., B.V.C., P.T.Q.), and the Hospital for Tropical Diseases (V.M.H., N.V.C., T.T.H.)— all in Ho Chi Minh City, Vietnam; and the Department of Microbiology, University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China (G.J.D.S., Y.G., J.S.M.P.).
Address reprint requests to Dr. de Jong at the Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 190 Ben Ham Tu, District 5, Ho Chi Minh City, Vietnam, or at mddejong@hcm.vnn.vn.
- References
References
1
The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5
Full Text | Web of Science | Medline2
Hien TT ,Liem NT ,Dung NT , et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350:1179-1188
Full Text | Web of Science | Medline3
Chotpitayasunondh T ,Ungchusak K ,Hanshaoworakul W , et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005;11:201-209
Web of Science | Medline4
Moscona A . Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-1373
Full Text | Web of Science | Medline5
Identification of influenza isolates by hemagglutination inhibition. In: Department of Communicable Disease Surveillance and Response. WHO manual on animal influenza diagnosis and surveillance. Geneva: World Health Organization, 2002:28-36. (WHO/CDS/CSR/NCS/2002.5.)
6
de Jong MD ,Cam BV ,Qui PT , et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005;352:686-691
Full Text | Web of Science | Medline7
Boom R ,Sol C ,Beld M ,Weel J ,Goudsmit J ,Wertheim-van Dillen P . Improved silica-guanidiniumthiocyanate DNA isolation procedure based on selective binding of bovine alpha-casein to silica particles. J Clin Microbiol 1999;37:615-619
Web of Science | Medline8
Boom R ,Sol CJ ,Salimans MM ,Jansen CL ,Wertheim-van Dillen PM ,van der Noordaa J . Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503
Web of Science | Medline9
Chen H ,Smith GJ ,Zhang SY , et al. Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature 2005;436:191-192
CrossRef | Web of Science | Medline10
Gubareva LV ,Kaiser L ,Matrosovich MN ,Soo-Hoo Y ,Hayden FG . Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001;183:523-531
CrossRef | Web of Science | Medline11
Le QM ,Kiso M ,Someya K , et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005;437:1108-1108
CrossRef | Web of Science | Medline12
Whitley RJ ,Hayden FG ,Reisinger KS , et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-133[Erratum, Pediatr Infect Dis J 2001;20:421.]
CrossRef | Web of Science | Medline13
Kiso M ,Mitamura K ,Sakai-Tagawa Y , et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759-765
CrossRef | Web of Science | Medline14
Ward P ,Small I ,Smith J ,Suter P ,Dutkowski R . Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55:Suppl 1:i5-i21
CrossRef | Web of Science | Medline15
Yen HL ,Monto AS ,Webster RG ,Govorkova EA . Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005;192:665-672
CrossRef | Web of Science | Medline16
Maines TR ,Lu XH ,Erb SM , et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 2005;79:11788-11800
CrossRef | Web of Science | Medline
- Citing Articles (224)
Citing Articles
1
Jarinrat Kongkamnerd, Adelaide Milani, Giovanni Cattoli, Calogero Terregino, Ilaria Capua, Luca Beneduce, Andrea Gallotta, Paolo Pengo, Giorgio Fassina, Stanislav Miertus, Wanchai De-Eknamkul. (2012) A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. Journal of Enzyme Inhibition and Medicinal Chemistry 27:1, 5-11
CrossRef2
Paul S. Keim. (2012) Q&A: Reasons for proposed redaction of flu paper. Nature
CrossRef3
Jarinrat Kongkamnerd, Luca Cappelletti, Adolfo Prandi, Pierfausto Seneci, Thanyada Rungrotmongkol, Nutthapon Jongaroonngamsang, Vladimir Frecer, Adelaide Milani, Giovanni Cattoli, Calogero Terregino, Ilaria Capua, Luca Beneduce, Andrea Gallotta, Paolo Pengo, Giorgio Fassina, Stanislav Miertus, Wanchai DeEknamkul. (2012) Synthesis and In vitro Study of Novel Neuraminidase Inhibitors Against Avian Influenza Virus. Bioorganic & Medicinal Chemistry
CrossRef4
Tarangsri Nivitchanyong, Suganya Yongkiettrakul, Jarin Kramyu, Supitcha Pannengpetch, Nanchaya Wanasen. (2011) Enhanced expression of secretable influenza virus neuraminidase in suspension mammalian cells by influenza virus nonstructural protein 1. Journal of Virological Methods 178:1-2, 44-51
CrossRef5
Shu-Chang An, Li-Li Xu, Feng-Di Li, Lin-Lin Bao, Chuan Qin, Zhan-Cheng Gao. (2011) Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic. Medical Hypotheses 77:6, 1054-1057
CrossRef6
Peng Bi-Hung, Yun Nadezhda, Chumakova Olga, Zacks Michele, Campbell Gerald, Smith Jeanon, Smith Jennifer, Linde Seth, Linde Jenna, Paessler Slobodan. (2011) Neuropathology of H5N1 Virus Infection in Ferrets. Veterinary Microbiology
CrossRef7
V. Yu. Marchenko, K. A. Sharshov, N. Yu. Silko, I. M. Susloparov, A. G. Durymanov, A. V. Zaykovskaya, A. Yu. Alekseev, O. V. Smolovskaya, A. P. Stefanenko, E. M. Malkova, A. M. Shestopalov. (2011) Characterization of the H5N1 influenza virus isolated during an outbreak among wild birds in Russia (Tuva Republic) in 2010. Molecular Genetics, Microbiology and Virology 26:4, 186-190
CrossRef8
Vanessa Escuret, Olivier Ferraris, Bruno Lina. (2011) The antiviral resistance of influenza virus. Therapy 8:6, 741-762
CrossRef9
James R. Smith, Craig R. Rayner, Barbara Donner, Martina Wollenhaupt, Klaus Klumpp, Regina Dutkowski. (2011) Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Advances in Therapy 28:11, 927-959
CrossRef10
Nicasio Mancini, Laura Solforosi, Nicola Clementi, Donata De Marco, Massimo Clementi, Roberto Burioni. (2011) A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Research 92:1, 15-26
CrossRef11
Geoffrey Chase, Kerstin Wunderlich, Peter Reuther, Martin Schwemmle. (2011) Identification of influenza virus inhibitors which disrupt of viral polymerase protein–protein interactions. Methods 55:2, 188-191
CrossRef12
Javier Magano. (2011) Recent synthetic approaches to oseltamivir phosphate (Tamiflu™) for the treatment of influenza. Tetrahedron 67:41, 7875-7899
CrossRef13
Dabo Pan, Huijun Sun, Yulin Shen, Huanxiang Liu, Xiaojun Yao. (2011) Exploring the molecular basis of dsRNA recognition by NS1 protein of influenza A virus using molecular dynamics simulation and free energy calculation. Antiviral Research
CrossRef14
S.M. Kang, J.M. Song, R.W. Compans. (2011) Novel vaccines against influenza viruses. Virus Research
CrossRef15
R. R. Razonable. (2011) Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. Mayo Clinic Proceedings 86:10, 1009-1026
CrossRef16
Trang Truc Nguyen, Binh Khanh Mai, Mai Suan Li. (2011) Study of Tamiflu Sensitivity to Variants of A/H5N1 Virus Using Different Force Fields. Journal of Chemical Information and Modeling 51:9, 2266-2276
CrossRef17
Konstantin H Müller, Denis E Kainov, Karim El Bakkouri, Xavier Saelens, Jef K De Brabander, Christian Kittel, Elisabeth Samm, Claude P Muller. (2011) The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. British Journal of Pharmacology 164:2, 344-357
CrossRef18
Zhongpeng Zhao, Fang Yan, Zhongwei Chen, Deyan Luo, Yueqiang Duan, Penghui Yang, Zhong Li, Daxin Peng, Xiufan Liu, Xiliang Wang. (2011) Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab′)2 against highly pathogenic avian influenza H5N1 in mice. International Immunopharmacology
CrossRef19
Tatiana Baranovich, Robert G Webster, Elena A Govorkova. (2011) Fitness of neuraminidase inhibitor-resistant influenza A viruses. Current Opinion in Virology
CrossRef20
Paolo Preziosi. (2011) Influenza pharmacotherapy: present situation, strategies and hopes. Expert Opinion on Pharmacotherapy 12:10, 1523-1549
CrossRef21
Ilyse Darwish, Samira Mubareka, W Conrad Liles. (2011) Immunomodulatory therapy for severe influenza. Expert Review of Anti-infective Therapy 9:7, 807-822
CrossRef22
Michal Raab, Igor Tvaroška. (2011) The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling. Journal of Molecular Modeling 17:6, 1445-1456
CrossRef23
Jie Dou, Lili Chen, Ge Xu, Lei Zhang, Huimin Zhou, Hui Wang, Zhenzhen Su, Mengyun Ke, Qinglong Guo, Changlin Zhou. (2011) Effects of baicalein on Sendai virus in vivo are linked to serum baicalin and its inhibition of hemagglutinin-neuraminidase. Archives of Virology 156:5, 793-801
CrossRef24
T. Ilyicheva, I. Susloparov, A. Durymanov, A. Romanovskaya, K. Sharshov, O. Kurskaya, M. Ignashkina, A. Shestopalov. (2011) Influenza A/H1N1pdm virus in Russian Asia in 2009–2010. Infection, Genetics and Evolution
CrossRef25
L. I. Ibanez, M. De Filette, A. Hultberg, T. Verrips, N. Temperton, R. A. Weiss, W. Vandevelde, B. Schepens, P. Vanlandschoot, X. Saelens. (2011) Nanobodies With In Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection. Journal of Infectious Diseases 203:8, 1063-1072
CrossRef26
Yu Liu, Fanbo Jing, Yingying Xu, Yuanchao Xie, Fangyuan Shi, Hao Fang, Minyong Li, Wenfang Xu. (2011) Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors. Bioorganic & Medicinal Chemistry 19:7, 2342-2348
CrossRef27
Yi Jin, Guozhong Zhang, Yanxin Hu, Meng Ding, Yi Li, Shanpin Cao, Jia Xue, Lun-Quan Sun, Ming Wang. (2011) Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib. The Journal of Gene Medicine 13:4, 243-249
CrossRef28
Ming-Sian Wu, Hung-Rong Yen, Chia-Wen Chang, Tsui-Yi Peng, Chung-Fan Hsieh, Chi-Jene Chen, Tzou-Yien Lin, Jim-Tong Horng. (2011) Mechanism of action of the suppression of influenza virus replication by Ko-Ken Tang through inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway and viral RNP nuclear export. Journal of Ethnopharmacology 134:3, 614-623
CrossRef29
J.-M. Song, N. Van Rooijen, J. Bozja, R. W. Compans, S.-M. Kang. (2011) Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proceedings of the National Academy of Sciences 108:2, 757-761
CrossRef30
Kristian Thorlund, Tahany Awad, Guy Boivin, Lehana Thabane. (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infectious Diseases 11:1, 134
CrossRef31
Hana M. Dobrovolny, Ronald Gieschke, Brian E. Davies, Nelson L. Jumbe, Catherine A.A. Beauchemin. (2011) Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. Journal of Theoretical Biology 269:1, 234-244
CrossRef32
A. Pizzorno, X. Bouhy, Y. Abed, G. Boivin. (2011) Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors. Journal of Infectious Diseases 203:1, 25-31
CrossRef33
Bin Wang, Megan C Steain, Dominic E Dwyer, Anthony L Cunningham, Nitin K Saksena. (2011) Synthetic long oligonucleotides to generate artificial templates for use as positive controls in molecular assays: drug resistance mutations in influenza virus as an example. Virology Journal 8:1, 405
CrossRef34
Yi Li, Yanxin Hu, Yi Jin, Guozhong Zhang, Jonathan Wong, Lun-Quan Sun, Ming Wang. (2011) Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection. The Journal of Gene Medicine 13:1, 60-72
CrossRef35
Wen He, Huamin Han, Wei Wang, Bin Gao. (2011) Anti-influenza virus effect of aqueous extracts from dandelion. Virology Journal 8:1, 538
CrossRef36
Ji-Rong Yang, Yuan-Pin Huang, Yu-Cheng Lin, Chun-Hui Su, Chuan-Yi Kuo, Li-Ching Hsu, Ho-Sheng Wu, Ming-Tsan Liu. (2010) Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. Antiviral Research 88:3, 256-262
CrossRef37
Anwar M. Hashem, Gary Van Domselaar, Changgui Li, Junzhi Wang, Yi-Min She, Terry D. Cyr, Jianhua Sui, Runtao He, Wayne A. Marasco, Xuguang Li. (2010) Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochemical and Biophysical Research Communications 403:2, 247-251
CrossRef38
C.-Y. Su, T.-J. R. Cheng, M.-I. Lin, S.-Y. Wang, W.-I. Huang, S.-Y. Lin-Chu, Y.-H. Chen, C.-Y. Wu, M. M. C. Lai, W.-C. Cheng, Y.-T. Wu, M.-D. Tsai, Y.-S. E. Cheng, C.-H. Wong. (2010) High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proceedings of the National Academy of Sciences 107:45, 19151-19156
CrossRef39
Hayato Ishikawa, Takaki Suzuki, Hideo Orita, Tadafumi Uchimaru, Yujiro Hayashi. (2010) High-Yielding Synthesis of the Anti-Influenza Neuraminidase Inhibitor (−)-Oseltamivir by Two “One-Pot” Sequences. Chemistry - A European Journal 16:42, 12616-12626
CrossRef40
Nicolas Widmer, Pascal Meylan, Anton Ivanyuk, Manel Aouri, Laurent A. Decosterd, Thierry Buclin. (2010) Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza. Clinical Pharmacokinetics 49:11, 741-765
CrossRef41
Jae-Min Song, Jaber Hossain, Dae-Goon Yoo, Aleksandr S. Lipatov, C. Todd Davis, Fu-Shi Quan, Li-Mei Chen, Robert J. Hogan, Ruben O. Donis, Richard W. Compans, Sang-Moo Kang. (2010) Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405:1, 165-175
CrossRef42
Aeron C. Hurt, Sue Lowther, Deborah Middleton, Ian G. Barr. (2010) Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Research 87:3, 361-366
CrossRef43
Christine Korteweg, Jiang Gu. (2010) Pandemic influenza A (H1N1) virus infection and avian influenza A (H5N1) virus infection: a comparative analysisThis paper is one of a selection of papers published in this special issue entitled “Second International Symposium on Recent Advances in Basic, Clinical, and Social Medicine” and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology 88:4, 575-587
CrossRef44
Tom Jefferson, Carlo Di Pietrantonj, Alessandro Rivetti, Ghada A Bawazeer, Lubna A Al-Ansary, Eliana Ferroni, Tom Jefferson. 2010. Vaccines for preventing influenza in healthy adults. .
CrossRef45
Bin Wang, Dominic E. Dwyer, Christopher C. Blyth, Maly Soedjono, Haijing Shi, Alison Kesson, Mala Ratnamohan, Ken McPhie, Anthony L. Cunningham, Nitin K. Saksena. (2010) Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Research 87:1, 16-21
CrossRef46
K. V. Chakravarthy, A. C. Bonoiu, W. G. Davis, P. Ranjan, H. Ding, R. Hu, J. B. Bowzard, E. J. Bergey, J. M. Katz, P. R. Knight, S. Sambhara, P. N. Prasad. (2010) Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proceedings of the National Academy of Sciences 107:22, 10172-10177
CrossRef47
Guillermo Ruiz-Carrascoso, Inmaculada Casas, Francisco Pozo, Carmen Pérez-González, Jordi Reina, Pilar Pérez-Breña. (2010) Development and implementation of influenza a virus subtyping and detection of genotypic resistance to neuraminidase inhibitors. Journal of Medical Virology 82:5, 843-853
CrossRef48
Vanessa Correia, Helena Rebelo de Andrade, Luís A. Santos, Angie Lackenby, Maria Zambon. (2010) Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons. Antiviral Research 86:2, 128-136
CrossRef49
Ruixue Wang, Jeffery K Taubenberger. (2010) Methods for molecular surveillance of influenza. Expert Review of Anti-infective Therapy 8:5, 517-527
CrossRef50
G. Milne, J. Kelso, H. Kelly. (2010) Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines. Journal of The Royal Society Interface 7:45, 573-586
CrossRef51
D. A. Boltz, B. Douangngeun, P. Phommachanh, S. Sinthasak, R. Mondry, C. Obert, P. Seiler, R. Keating, Y. Suzuki, H. Hiramatsu, E. A. Govorkova, R. G. Webster. (2010) Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. Journal of General Virology 91:4, 949-959
CrossRef52
Neetu Singh, Aseem Pandey, Suresh K. Mittal. (2010) Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Reviews in Molecular Medicine 12,
CrossRef53
Andrea K. Boggild, Allison J. McGeer. (2010) Laboratory diagnosis of 2009 H1N1 influenza A virus. Critical Care Medicine 38, e38-e42
CrossRef54
Anete Trajman, Dick Menzies. (2010) Occupational respiratory infections. Current Opinion in Pulmonary Medicine1
CrossRef55
Jonathan P Wong, Mary E Christopher, Satya Viswanathan, Glen Schnell, Xiaojiang Dai, Donald Van Loon, Eric R Stephen. (2010) Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza. Expert Review of Respiratory Medicine 4:2, 171-177
CrossRef56
J. R. Smith. (2010) Oseltamivir in human avian influenza infection. Journal of Antimicrobial Chemotherapy 65:Supplement 2, ii25-ii33
CrossRef57
Jagadeeshwar R. Rao, Ashok K. Jha, Ravindra K. Rawal, Ashoke Sharon, Craig W. Day, Dale L. Barnard, Donald F. Smee, Chung K. Chu. (2010) (−)-Carbodine: Enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu). Bioorganic & Medicinal Chemistry Letters 20:8, 2601-2604
CrossRef58
Michael J. Loeffelholz. (2010) Avian Influenza A H5N1 Virus. Clinics in Laboratory Medicine 30:1, 1-20
CrossRef59
Nadine Rouphael Maakaroun, Abeer Moanna, Jesse T Jacob, Helmut Albrecht. (2010) Viral infections associated with haemophagocytic syndrome. Reviews in Medical Virology 20:2, 93-105
CrossRef60
Alam Jahangir, Sakchai Ruenphet, Dany Shoham, Masashi Okamura, Masayuki Nakamaura, Kazuaki Takehara. (2010) Haemagglutinin and neuraminidase characterization of low pathogenic H5 and H7 avian influenza viruses isolated from Northern pintails (Anas acuta) in Japan, with special reference to genomic and biogeographical aspects. Virus Genes 40:1, 94-105
CrossRef61
M. Kiso, K. Takahashi, Y. Sakai-Tagawa, K. Shinya, S. Sakabe, Q. M. Le, M. Ozawa, Y. Furuta, Y. Kawaoka. (2010) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proceedings of the National Academy of Sciences 107:2, 882-887
CrossRef62
S.-R. Shih, J.-T. Horng, L. L. M. Poon, T.-C. Chen, J.-Y. Yeh, H.-P. Hsieh, S.-N. Tseng, C. Chiang, W.-L. Li, Y.-S. Chao, J. T.-A. Hsu. (2010) BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses. Journal of Antimicrobial Chemotherapy 65:1, 63-71
CrossRef63
W.R.J. Taylor, E. Burhan, H. Wertheim, P.Z. Soepandi, P. Horby, A. Fox, R. Benamore, L. de Simone, T.T. Hien, F. Chappuis. (2010) Avian influenza – A review for doctors in travel medicine. Travel Medicine and Infectious Disease 8:1, 1-12
CrossRef64
Tom Jefferson, Chris Del Mar, Liz Dooley, Eliana Ferroni, Lubna A Al-Ansary, Ghada A Bawazeer, Mieke L van Driel, Sreekumaran Nair, Ruth Foxlee, Alessandro Rivetti. 2010. .
CrossRef65
Hu Ge, Yi-Fei Wang, Jun Xu, Qiong Gu, Hai-Bo Liu, Pei-Gen Xiao, Jiaju Zhou, Yanhuai Liu, Zirong Yang, Hua Su. (2010) Anti-influenza agents from Traditional Chinese Medicine. Natural Product Reports 27:12, 1758
CrossRef66
Jean-Michel Garcia, Nadège Lagarde, Edward S.K. Ma, Menno D. de Jong, J.S. Malik Peiris. (2010) Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. Journal of Clinical Virology 47:1, 29-33
CrossRef67
Shi-gui Yang, Jian-er Wo, Min-wei Li, Fen-fang Mi, Cheng-bo Yu, Guo-liang Lv, Hong-Cui Cao, Hai-feng Lu, Bao-hong Wang, Hanping Zhu, Lan-Juan Li. (2010) Expression of H5N1 influenza virus hemagglutinin protein fused with protein transduction domain in an alphavirus replicon system. Journal of Virological Methods 163:1, 31-39
CrossRef68
E. van der Vries, M. Jonges, S. Herfst, J. Maaskant, A. Van der Linden, J. Guldemeester, G.I. Aron, T.M. Bestebroer, M. Koopmans, A. Meijer, R.A.M. Fouchier, A.D.M.E. Osterhaus, C.A. Boucher, M. Schutten. (2010) Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. Journal of Clinical Virology 47:1, 34-37
CrossRef69
Phillip Andrew Reece. (2010) Zanamivir for the treatment of avian influenza infections in humans. Expert Review of Clinical Pharmacology 3:1, 25-29
CrossRef70
Baz, Mariana, Abed, Yacine, Papenburg, Jesse, Bouhy, Xavier, Hamelin, Marie-Ève, Boivin, Guy, . (2009) Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis. New England Journal of Medicine 361:23, 2296-2297
Full Text71
Mehran Haidari, Muzammil Ali, Samuel Ward Casscells, Mohammad Madjid. (2009) Pomegranate (Punica granatum) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir. Phytomedicine 16:12, 1127-1136
CrossRef72
Xiaojing Lin, Jianfang Zhou, Yonghui Zhang, Jia Wu, Fengwei Zhang, Zi Li, Ye Zhang, Shengli Bi, Yuelong Shu, Yue Wang. (2009) Oseltamivir boosts 2009 H1N1 virus infectivity in vitro. Biochemical and Biophysical Research Communications 390:4, 1305-1308
CrossRef73
Jianjun Chen, Fang Fang, Zhongdong Yang, Xueying Liu, Hongbo Zhang, Zhiping Zhang, Xianen Zhang, Ze Chen. (2009) Characterization of highly pathogenic H5N1 avian influenza viruses isolated from poultry markets in central China. Virus Research 146:1-2, 19-28
CrossRef74
Aeron C. Hurt, Jessica K. Holien, Michael W. Parker, Ian G. Barr. (2009) Oseltamivir Resistance and the H274Y Neuraminidase Mutation in Seasonal, Pandemic and Highly Pathogenic Influenza Viruses. Drugs 69:18, 2523-2531
CrossRef75
Thanyada Rungrotmongkol, Thanyarat Udommaneethanakit, Maturos Malaisree, Nadtanet Nunthaboot, Pathumwadee Intharathep, Pornthep Sompornpisut, Supot Hannongbua. (2009) How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants?. Biophysical Chemistry 145:1, 29-36
CrossRef76
Michael G Ison. (2009) Anti-influenza therapy: the emerging challenge of resistance. Therapy 6:6, 883-891
CrossRef77
P.J. Collins, L.F. Haire, Y.P. Lin, J. Liu, R.J. Russell, P.A. Walker, S.R. Martin, R.S. Daniels, V. Gregory, J.J. Skehel, S.J. Gamblin, A.J. Hay. (2009) Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27:45, 6317-6323
CrossRef78
Erin Saleeby, Jocelyn Chapman, Jessica Morse, Allison Bryant. (2009) H1N1 Influenza in Pregnancy. Obstetrics & Gynecology 114:4, 885-891
CrossRef79
Zeyu Liu, Zhongmin Guo, Guoling Wang, Dingmei Zhang, Hongxuan He, Guowei Li, Yuge Liu, Denise Higgins, Aoiffe Walsh, Leo Shanahan-Prendergast, Jiahai Lu. (2009) Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. European Journal of Pharmaceutical Sciences 38:3, 215-223
CrossRef80
Maturos Malaisree, Thanyada Rungrotmongkol, Nadtanet Nunthaboot, Ornjira Aruksakunwong, Pathumwadee Intharathep, Panita Decha, Pornthep Sompornpisut, Supot Hannongbua. (2009) Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. Amino Acids 37:4, 725-732
CrossRef81
Kaori Suzuki, Jun-Ichi Sakamoto, Tetsuo Koyama, Sangchai Yingsakmongkon, Yasuo Suzuki, Ken Hatano, Daiyo Terunuma, Koji Matsuoka. (2009) Synthesis of sialic acid derivatives having a CC double bond substituted at the C-5 position and their glycopolymers. Bioorganic & Medicinal Chemistry Letters 19:17, 5105-5108
CrossRef82
Jun-Ichi Sakamoto, Tetsuo Koyama, Daisei Miyamoto, Sangchai Yingsakmongkon, Kazuya I.P.J. Hidari, Wipawee Jampangern, Takashi Suzuki, Yasuo Suzuki, Yasuaki Esumi, Takemichi Nakamura, Ken Hatano, Daiyo Terunuma, Koji Matsuoka. (2009) Systematic syntheses of influenza neuraminidase inhibitors: A series of carbosilane dendrimers uniformly functionalized with thioglycoside-type sialic acid moieties. Bioorganic & Medicinal Chemistry 17:15, 5451-5464
CrossRef83
Shu-Qing Wang, Qi-Shi Du, Ri-Bo Huang, Da-Wei Zhang, Kuo-Chen Chou. (2009) Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Biochemical and Biophysical Research Communications 386:3, 432-436
CrossRef84
Varough M Deyde, Larisa V Gubareva. (2009) Influenza genome analysis using pyrosequencing method: current applications for a moving target. Expert Review of Molecular Diagnostics 9:5, 493-509
CrossRef85
Marguerite Pappaioanou. (2009) Highly pathogenic H5N1 avian influenza virus: Cause of the next pandemic?. Comparative Immunology, Microbiology and Infectious Diseases 32:4, 287-300
CrossRef86
Murray E. Alexander, Sarah M. Dietrich, Yi Hua, Seyed M. Moghadas. (2009) A comparative evaluation of modelling strategies for the effect of treatment and host interactions on the spread of drug resistance. Journal of Theoretical Biology 259:2, 253-263
CrossRef87
C. Fraser, C. A. Donnelly, S. Cauchemez, W. P. Hanage, M. D. Van Kerkhove, T. D. Hollingsworth, J. Griffin, R. F. Baggaley, H. E. Jenkins, E. J. Lyons, T. Jombart, W. R. Hinsley, N. C. Grassly, F. Balloux, A. C. Ghani, N. M. Ferguson, A. Rambaut, O. G. Pybus, H. Lopez-Gatell, C. M. Alpuche-Aranda, I. B. Chapela, E. P. Zavala, D. Ma. E. Guevara, F. Checchi, E. Garcia, S. Hugonnet, C. Roth, . (2009) Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings. Science 324:5934, 1557-1561
CrossRef88
Gabriele Neumann, Takeshi Noda, Yoshihiro Kawaoka. (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:7249, 931-939
CrossRef89
D. M. Fleming, A. J. Elliot, A. Meijer, W. J. Paget. (2009) Influenza virus resistance to oseltamivir: what are the implications?. The European Journal of Public Health 19:3, 238-239
CrossRef90
Robert M. Krug, James M. Aramini. (2009) Emerging antiviral targets for influenza A virus. Trends in Pharmacological Sciences 30:6, 269-277
CrossRef91
S. Bolotin, A.V. Robertson, A. Eshaghi, C. De Lima, E. Lombos, E. Chong-King, L. Burton, T. Mazzulli, S.J. Drews. (2009) Development of a novel real-time reverse-transcriptase PCR method for the detection of H275Y positive influenza A H1N1 isolates. Journal of Virological Methods 158:1-2, 190-194
CrossRef92
Zoltan Vajo. (2009) Influenza A (H5N1) pandemic prototype vaccine Fluval ®. Expert Review of Vaccines 8:5, 619-624
CrossRef93
Yan Jiang, Yueling Wang, Yu Kuang, Baoning Wang, Wanyi Li, Tianxiang Gong, Zhonghua Jiang, De Yang, Mingyuan Li. (2009) Expression of mouse beta-defensin-3 in MDCK cells and its anti-influenza-virus activity. Archives of Virology 154:4, 639-647
CrossRef94
Fred Y. Aoki, Guy Boivin. (2009) Influenza virus shedding—Excretion patterns and effects of antiviral treatment. Journal of Clinical Virology 44:4, 255-261
CrossRef95
Lizheng Guo, Rebecca J. Garten, Angie S. Foust, Wendy M. Sessions, Margaret Okomo-Adhiambo, Larisa V. Gubareva, Alexander I. Klimov, Xiyan Xu. (2009) Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antiviral Research 82:1, 29-33
CrossRef96
Benoit Carbain, Patrick J. Collins, Lori Callum, Stephen R. Martin, Alan J. Hay, John McCauley, Hansjörg Streicher. (2009) Efficient Synthesis of Highly Active Phospha-Isosteres of the Influenza Neuraminidase Inhibitor Oseltamivir. ChemMedChem 4:3, 335-337
CrossRef97
Jianhua Sui, William C Hwang, Sandra Perez, Ge Wei, Daniel Aird, Li-mei Chen, Eugenio Santelli, Boguslaw Stec, Greg Cadwell, Maryam Ali, Hongquan Wan, Akikazu Murakami, Anuradha Yammanuru, Thomas Han, Nancy J Cox, Laurie A Bankston, Ruben O Donis, Robert C Liddington, Wayne A Marasco. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Structural & Molecular Biology 16:3, 265-273
CrossRef98
Andrew W. Hill, Robert P. Guralnick, Meredith J.C. Wilson, Farhat Habib, Daniel Janies. (2009) Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza. Infection, Genetics and Evolution 9:2, 169-178
CrossRef99
S. Yongkiettrakul, K. Boonyapakron, A. Jongkaewwattana, A. Wanitchang, U. Leartsakulpanich, P. Chitnumsub, L. Eurwilaichitr, Y. Yuthavong. (2009) Avian influenza A/H5N1 neuraminidase expressed in yeast with a functional head domain. Journal of Virological Methods 156:1-2, 44-51
CrossRef100
Iain Stephenson, Jane Democratis, Angie Lackenby, Teresa McNally, James Smith, Manish Pareek, Joanna Ellis, Alison Bermingham, Karl Nicholson, Maria Zambon. (2009) Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children. Clinical Infectious Diseases 48:4, 389-396
CrossRef101
Charlotte D'Souza, Meena Kanyalkar, Mamata Joshi, Evans Coutinho, Sudha Srivastava. (2009) Probing molecular level interaction of oseltamivir with H5N1-NA and model membranes by molecular docking, multinuclear NMR and DSC methods. Biochimica et Biophysica Acta (BBA) - Biomembranes 1788:2, 484-494
CrossRef102
Hui-Chen Hung, Ching-Ping Tseng, Jinn-Moon Yang, Yi-Wei Ju, Sung-Nain Tseng, Yen-Fu Chen, Yu-Sheng Chao, Hsing-Pang Hsieh, Shin-Ru Shih, John T.-A. Hsu. (2009) Aurintricarboxylic acid inhibits influenza virus neuraminidase. Antiviral Research 81:2, 123-131
CrossRef103
Jianjun Chen, Zhongdong Yang, Quanjiao Chen, Xueying Liu, Fang Fang, Haiyan Chang, Dongmei Li, Ze Chen. (2009) Characterization of H5N1 influenza A viruses isolated from domestic green-winged teal. Virus Genes 38:1, 66-73
CrossRef104
Yuk-Fai Lau, Lay-Hoon Tang, Eng-Eong Ooi. (2009) A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27:9, 1354-1364
CrossRef105
A. Maxmen. (2009) Jeremy Farrar: When disaster strikes. Journal of Experimental Medicine 206:1, 4-5
CrossRef106
Jian-Xin Chen, Hui-Jun Xue, Wen-Cai Ye, Bing-Hu Fang, Ya-Hong Liu, Shao-Hua Yuan, Pei Yu, Yu-Qiang Wang. (2009) Activity of Andrographolide and Its Derivatives against Influenza Virus in Vivo and in Vitro. Biological & Pharmaceutical Bulletin 32:8, 1385-1391
CrossRef107
Frederick Hayden. (2009) Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?. Clinical Infectious Diseases 48:S1, S3-S13
CrossRef108
Varough M. Deyde, Margaret Okomo-Adhiambo, Tiffany G. Sheu, Teresa R. Wallis, Alicia Fry, Nila Dharan, Alexander I. Klimov, Larisa V. Gubareva. (2009) Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Research 81:1, 16-24
CrossRef109
Carmen Nájera, José M. Sansano. (2009) 1,3-Dipolar cycloadditions: applications to the synthesis of antiviral agents. Organic & Biomolecular Chemistry 7:22, 4567
CrossRef110
Kenneth C. Earhart, Nasr M. Elsayed, Magdi D. Saad, Larisa V. Gubareva, Ahmed Nayel, Varough M. Deyde, Ali Abdelsattar, Ahmad S. Abdelghani, Bruce R. Boynton, Moustafa M. Mansour, Hala M. Essmat, Alexander Klimov, Deidra Shuck-Lee, M.R. Monteville, Jeffrey A. Tjaden. (2009) Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. Journal of Infection and Public Health 2:2, 74-80
CrossRef111
Kenneth W. TSANG, Thomas M. FILE Jr. (2008) Respiratory infections unique to Asia. Respirology 13:7, 937-949
CrossRef112
Susanne Duwe, Brunhilde Schweiger. (2008) A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. Journal of Virological Methods 153:2, 134-141
CrossRef113
J. Gabbard, N. Velappan, R. Di Niro, J. Schmidt, C.A. Jones, S.M. Tompkins, A.R.M. Bradbury. (2008) A humanized anti-M2 scFv shows protective in vitro activity against influenza. Protein Engineering Design and Selection 22:3, 189-198
CrossRef114
Simmons, Cameron, Farrar, Jeremy, . (2008) Insights into Inflammation and Influenza. New England Journal of Medicine 359:15, 1621-1623
Full Text115
R.C.-S. Seet, E.C.H. Lim, V.M.S. Oh, B.K.C. Ong, K.T. Goh, D.A. Fisher, K.Y. Ho, K.G. Yeoh. (2008) Readiness exercise to combat avian influenza. QJM 102:2, 133-137
CrossRef116
Menno D. de Jong. (2008) H5N1 Transmission and Disease. The Pediatric Infectious Disease Journal 27:Supplement, S54-S56
CrossRef117
Arnold S. Monto. (2008) Antivirals and Influenza. The Pediatric Infectious Disease Journal 27:Supplement, S110-S112
CrossRef118
Samson S.Y. WONG, Kwok-Yung YUEN. (2008) Antiviral therapy for respiratory tract infections. Respirology
CrossRef119
S. M. Mniszewski, S. Y. Del Valle, P. D. Stroud, J. M. Riese, S. J. Sydoriak. (2008) Pandemic simulation of antivirals + school closures: buying time until strain-specific vaccine is available. Computational and Mathematical Organization Theory 14:3, 209-221
CrossRef120
Suki M. Y. Lee, Chung‐Yan Cheung, John M. Nicholls, Kenrie P. Y. Hui, Connie Y. H. Leung, Mongkol Uiprasertkul, George L. Tipoe, Yu‐Lung Lau, Leo L. M. Poon, Nancy Y. Ip, Yi Guan, J. S. Malik Peiris. (2008) Hyperinduction of Cyclooxygenase‐2–Mediated Proinflammatory Cascade: A Mechanism for the Pathogenesis of Avian Influenza H5N1 Infection. The Journal of Infectious Diseases 198:4, 525-535
CrossRef121
Matthew J. Memoli, David M. Morens, Jeffery K. Taubenberger. (2008) Pandemic and seasonal influenza: therapeutic challenges. Drug Discovery Today 13:13-14, 590-595
CrossRef122
Patrick J. Collins, Lesley F. Haire, Yi Pu Lin, Junfeng Liu, Rupert J. Russell, Philip A. Walker, John J. Skehel, Stephen R. Martin, Alan J. Hay, Steven J. Gamblin. (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:7199, 1258-1261
CrossRef123
Catherine WM Ong, Paul Ananth Tambyah. (2008) Update on antivirals and vaccines for seasonal and potential pandemic use. Expert Review of Respiratory Medicine 2:3, 391-402
CrossRef124
Xiaowen Cheng, Chunli Wu, Jianfan He, Xing Lv, Shunxiang Zhang, Li Zhou, Jingwen Wang, Riqiang Deng, Qingxing Long, Xunzhang Wang, Jinquan Cheng. (2008) Serologic and genetic characterization analyses of a highly pathogenic influenza virus (H5N1) isolated from an infected man in Shenzhen. Journal of Medical Virology 80:6, 1058-1064
CrossRef125
S. M Moghadas. (2008) Management of drug resistance in the population: influenza as a case study. Proceedings of the Royal Society B: Biological Sciences 275:1639, 1163-1169
CrossRef126
Christine Korteweg, Jiang Gu. (2008) Pathology, Molecular Biology, and Pathogenesis of Avian Influenza A (H5N1) Infection in Humans. The American Journal of Pathology 172:5, 1155-1170
CrossRef127
Christopher Lupfer, David A. Stein, Dan V. Mourich, Samuel E. Tepper, Patrick L. Iversen, Manoj Pastey. (2008) Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers. Archives of Virology 153:5, 929-937
CrossRef128
Nedaa Skeik, Fadi I. Jabr. (2008) Influenza viruses and the evolution of avian influenza virus H5N1. International Journal of Infectious Diseases 12:3, 233-238
CrossRef129
David A. Boltz, Jerold E. Rehg, Jennifer McClaren, Robert G. Webster, Elena A. Govorkova. (2008) Oseltamivir Prophylactic Regimens Prevent H5N1 Influenza Morbidity and Mortality in a Ferret Model. The Journal of Infectious Diseases 197:9, 1315-1323
CrossRef130
Michael P. Atkinson, Lawrence M. Wein. (2008) Quantifying the Routes of Transmission for Pandemic Influenza. Bulletin of Mathematical Biology 70:3, 820-867
CrossRef131
John Beigel, Mike Bray. (2008) Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Research 78:1, 91-102
CrossRef132
Andrea Gambotto, Simon M Barratt-Boyes, Menno D de Jong, Gabriele Neumann, Yoshihiro Kawaoka. (2008) Human infection with highly pathogenic H5N1 influenza virus. The Lancet 371:9622, 1464-1475
CrossRef133
G. Gabriel, A. Nordmann, D. A. Stein, P. L. Iversen, H.-D. Klenk. (2008) Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus. Journal of General Virology 89:4, 939-948
CrossRef134
Nadezhda E. Yun, Nathaniel S. Linde, Michele A. Zacks, Ian G. Barr, Aeron C. Hurt, Jeanon N. Smith, Natallia Dziuba, Michael R. Holbrook, Lifang Zhang, John M. Kilpatrick, C. Shane Arnold, Slobodan Paessler. (2008) Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 374:1, 198-209
CrossRef135
Michael B. Rothberg, Sarah D. Haessler, Richard B. Brown. (2008) Complications of Viral Influenza. The American Journal of Medicine 121:4, 258-264
CrossRef136
Arnold S. Monto, Richard J. Whitley. (2008) Seasonal and Pandemic Influenza: A 2007 Update on Challenges and Solutions. Clinical Infectious Diseases 46:7, 1024-1031
CrossRef137
Paul A. TAMBYAH. (2008) Update on influenza vaccines. Respirology 13:s1, S41-S43
CrossRef138
Marie-Anne Rameix-Welti, Sylvie van der Werf, Nadia Naffakh. (2008) Sensitivity of H5N1 influenza viruses to oseltamivir: an update. Future Virology 3:2, 157-165
CrossRef139
Alex J Elliot, Douglas M Fleming. (2008) Influenza and respiratory syncytial virus in the elderly. Expert Review of Vaccines 7:2, 249-258
CrossRef140
Paul A. TAMBYAH. (2008) Update on influenza anti-virals. Respirology 13:s1, S19-S21
CrossRef141
Yacine Abed, Benjamin Nehmé, Mariana Baz, Guy Boivin. (2008) Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Research 77:2, 163-166
CrossRef142
Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. (2008) Update on Avian Influenza A (H5N1) Virus Infection in Humans. New England Journal of Medicine 358:3, 261-273
Full Text143
Tran Tan Thanh, H. Rogier van Doorn, Menno D. de Jong. (2008) Human H5N1 influenza: Current insight into pathogenesis. The International Journal of Biochemistry & Cell Biology 40:12, 2671-2674
CrossRef144
Olivier Ferraris, Bruno Lina. (2008) Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. Journal of Clinical Virology 41:1, 13-19
CrossRef145
Vanessa Escuret, Emilie Frobert, Maude Bouscambert-Duchamp, Murielle Sabatier, Isidore Grog, Martine Valette, Bruno Lina, Florence Morfin, Olivier Ferraris. (2008) Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. Journal of Clinical Virology 41:1, 25-28
CrossRef146
Jessica A. Belser, Xiuhua Lu, Kristy J. Szretter, Xiaoping Jin, Laura M. Aschenbrenner, Alice Lee, Stephen Hawley, Do Hyong Kim, Michael P. Malakhov, Mang Yu, Fang Fang, Jacqueline M. Katz. (2007) DAS181, A Novel Sialidase Fusion Protein, Protects Mice from Lethal Avian Influenza H5N1 Virus Infection. The Journal of Infectious Diseases 196:10, 1493-1499
CrossRef147
Robert C. Moellering, John R. Graybill, John E. McGowan, Lawrence Corey. (2007) Antimicrobial resistance prevention initiative—an update: Proceedings of an expert panel on resistance. American Journal of Infection Control 35:9, S1-S23
CrossRef148
J. A. Linder. (2007) Improving Care for Acute Respiratory Infections: Better Systems, Not Better Microbiology. Clinical Infectious Diseases 45:9, 1189-1191
CrossRef149
F. Debarre, S. Bonhoeffer, R. R Regoes. (2007) The effect of population structure on the emergence of drug resistance during influenza pandemics. Journal of The Royal Society Interface 4:16, 893-906
CrossRef150
Zhou, Boping, , Zhong, Nanshan, , Guan, Yi, . (2007) Treatment with Convalescent Plasma for Influenza A (H5N1) Infection. New England Journal of Medicine 357:14, 1450-1451
Full Text151
Qi-Shi Du, Shu-Qing Wang, Kuo-Chen Chou. (2007) Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochemical and Biophysical Research Communications 362:2, 525-531
CrossRef152
Richard J Whitley. (2007) The role of oseltamivir in the treatment and prevention of influenza in children. Expert Opinion on Drug Metabolism & Toxicology 3:5, 755-767
CrossRef153
Phillip Andrew Reece. (2007) Neuraminidase inhibitor resistance in influenza viruses. Journal of Medical Virology 79:10, 1577-1586
CrossRef154
Yaji Xu, Linda J.S. Allen, Alan S. Perelson. (2007) Stochastic model of an influenza epidemic with drug resistance. Journal of Theoretical Biology 248:1, 179-193
CrossRef155
Katja Bauer, Christina Schrader, Jochen Suess, Peter Wutzler, Michaela Schmidtke. (2007) Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999. Antiviral Research 75:3, 219-226
CrossRef156
Jindrich Cinatl, Martin Michaelis, Hans W. Doerr. (2007) The threat of avian influenza A (H5N1). Part III: antiviral therapy. Medical Microbiology and Immunology 196:4, 203-212
CrossRef157
M. E Alexander, C. S Bowman, Z. Feng, M. Gardam, S. M Moghadas, G. Rost, J. Wu, P. Yan. (2007) Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proceedings of the Royal Society B: Biological Sciences 274:1619, 1675-1684
CrossRef158
Koji Matsuoka, Chiharu Takita, Tetsuo Koyama, Daisei Miyamoto, Sangchai Yingsakmongkon, Kazuya I.P.J. Hidari, Wipawee Jampangern, Takashi Suzuki, Yasuo Suzuki, Ken Hatano, Daiyo Terunuma. (2007) Novel linear polymers bearing thiosialosides as pendant-type epitopes for influenza neuraminidase inhibitors. Bioorganic & Medicinal Chemistry Letters 17:14, 3826-3830
CrossRef159
K. Lee, D. Fidler. (2007) Avian and pandemic influenza: Progress and problems with global health governance. Global Public Health 2:3, 215-234
CrossRef160
Robert C. Moellering, John R. Graybill, John E. McGowan, Lawrence Corey. (2007) Antimicrobial Resistance Prevention Initiative—An Update: Proceedings of an Expert Panel on Resistance. The American Journal of Medicine 120:7, S4-S25
CrossRef161
Robin B. McFee. (2007) Avian Influenza: The Next Pandemic?. Disease-a-Month 53:7, 348-387
CrossRef162
Paul J. Drinka, Tom Haupt. (2007) Emergence of Rimantadine-Resistant Virus Within 6 Days of Starting Rimantadine Prophylaxis with Oseltamivir Treatment of Symptomatic Cases. Journal of the American Geriatrics Society 55:6, 923-926
CrossRef163
Yaseen Arabi, Charles D. Gomersall, Qanta A. Ahmed, Bruce R. Boynton, Ziad A. Memish. (2007) The critically ill avian influenza A (H5N1) patient*. Critical Care Medicine 35:5, 1397-1403
CrossRef164
Scott T Rottinghaus, Richard J Whitley. (2007) Current non-AIDS antiviral chemotherapy. Expert Review of Anti-infective Therapy 5:2, 217-230
CrossRef165
R. F. Chemaly, H. A. Torres, E. A. Aguilera, G. Mattiuzzi, M. Cabanillas, H. Kantarjian, V. Gonzalez, A. Safdar, I. I. Raad. (2007) Neuraminidase Inhibitors Improve Outcome of Patients with Leukemia and Influenza: An Observational Study. Clinical Infectious Diseases 44:7, 964-967
CrossRef166
K. Bragstad, P. H. Jørgensen, K. J. Handberg, A. Fomsgaard. (2007) Genome characterisation of the newly discovered avian influenza A H5N7 virus subtype combination. Archives of Virology 152:3, 585-593
CrossRef167
Emanuele Montomoli, Ilaria Manini. (2007) Pre-emptive vaccination against pandemic influenza virus. Vaccine 25:11, 1921-1922
CrossRef168
L. A. Mandell, R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, D. M. Musher, M. S. Niederman, A. Torres, C. G. Whitney. (2007) Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases 44:Supplement 2, S27-S72
CrossRef169
Shu-Qing Wang, Qi-Shi Du, Kou-Chen Chou. (2007) Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochemical and Biophysical Research Communications 354:3, 634-640
CrossRef170
Richard A Martinello. (2007) Preparing for avian influenza. Current Opinion in Pediatrics 19:1, 64-70
CrossRef171
Jun-Ichi Sakamoto, Tetsuo Koyama, Daisei Miyamoto, Sangchai Yingsakmongkon, Kazuya I.P.J. Hidari, Wipawee Jampangern, Takashi Suzuki, Yasuo Suzuki, Yasuaki Esumi, Ken Hatano, Daiyo Terunuma, Koji Matsuoka. (2007) Thiosialoside clusters using carbosilane dendrimer core scaffolds as a new class of influenza neuraminidase inhibitors. Bioorganic & Medicinal Chemistry Letters 17:3, 717-721
CrossRef172
John S. Oxford. (2007) Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza and Other Respiratory Viruses 1:1, 27-34
CrossRef173
Salin Chutinimitkul, Kamol Suwannakarn, Thaweesak Chieochansin, Le Quynh Mai, Sudarat Damrongwatanapokin, Arunee Chaisingh, Alongkorn Amonsin, Olfert Landt, Thaweesak Songserm, Apiradee Theamboonlers, Yong Poovorawan. (2007) H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. Journal of Virological Methods 139:1, 44-49
CrossRef174
Holger J Schünemann, Suzanne R Hill, Meetali Kakad, Richard Bellamy, Timothy M Uyeki, Frederick G Hayden, Yazdan Yazdanpanah, John Beigel, Tawee Chotpitayasunondh, Chris Del Mar, Jeremy Farrar, Tran Tinh Hien, Bülent Özbay, Norio Sugaya, Keiji Fukuda, Nikki Shindo, Lauren Stockman, Gunn E Vist, Alice Croisier, Azim Nagjdaliyev, Cathy Roth, Gail Thomson, Howard Zucker, Andrew D Oxman. (2007) WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. The Lancet Infectious Diseases 7:1, 21-31
CrossRef175
Ingi Lee, Todd D Barton. (2007) Viral Respiratory Tract Infections in Transplant Patients. Drugs 67:10, 1411-1427
CrossRef176
Agostino Pugliese, Tiziana Beltramo, Donato Torre. (2007) Emerging and re-emerging viral infections in Europe. Cell Biochemistry and Function 25:1, 1-13
CrossRef177
James W. Noah, William Severson, Diana L. Noah, Lynn Rasmussen, E. Lucile White, Colleen B. Jonsson. (2007) A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Research 73:1, 50-59
CrossRef178
L. Kaiser. (2006) Influenza Will Not Miss Opportunities. Clinical Infectious Diseases 43:12, 1562-1564
CrossRef179
Erik De Clercq. (2006) Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery 5:12, 1015-1025
CrossRef180
Kandun, I. Nyoman, Wibisono, Hariadi, Sedyaningsih, Endang R., Yusharmen, Hadisoedarsuno, Widarso, Purba, Wilfried, Santoso, Hari, Septiawati, Chita, Tresnaningsih, Erna, Heriyanto, Bambang, Yuwono, Djoko, Harun, Syahrial, Soeroso, Santoso, Giriputra, Sardikin, Blair, Patrick J., Jeremijenko, Andrew, Kosasih, Herman, Putnam, Shannon D., Samaan, Gina, Silitonga, Marlinggom, Chan, K.H., Poon, Leo L.M., Lim, Wilina, Klimov, Alexander, Lindstrom, Stephen, Guan, Yi, Donis, Ruben, Katz, Jacqueline, Cox, Nancy, Peiris, Malik, Uyeki, Timothy M., . (2006) Three Indonesian Clusters of H5N1 Virus Infection in 2005. New England Journal of Medicine 355:21, 2186-2194
Full Text181
Menno D de Jong, Cameron P Simmons, Tran Tan Thanh, Vo Minh Hien, Gavin J D Smith, Tran Nguyen Bich Chau, Dang Minh Hoang, Nguyen Van Vinh Chau, Truong Huu Khanh, Vo Cong Dong, Phan Tu Qui, Bach Van Cam, Do Quang Ha, Yi Guan, J S Malik Peiris, Nguyen Tran Chinh, Tran Tinh Hien, Jeremy Farrar. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nature Medicine 12:10, 1203-1207
CrossRef182
Andrea Morgan. (2006) Avian Influenza: An Agricultural Perspective. The Journal of Infectious Diseases 194:s2, S139-S146
CrossRef183
Adolfo García‐Sastre, Richard J. Whitley. (2006) Lessons Learned from Reconstructing the 1918 Influenza Pandemic. The Journal of Infectious Diseases 194:s2, S127-S132
CrossRef184
Martin Petric, Lorraine Comanor, Cathy A. Petti. (2006) Role of the Laboratory in Diagnosis of Influenza during Seasonal Epidemics and Potential Pandemics. The Journal of Infectious Diseases 194:s2, S98-S110
CrossRef185
Richard J. Whitley, John Bartlett, Frederick G. Hayden, Andrew T. Pavia, Michael Tapper, Arnold S. Monto. (2006) Seasonal and Pandemic Influenza: Recommendations for Preparedness in the United States. The Journal of Infectious Diseases 194:s2, S155-S161
CrossRef186
Frederick G. Hayden, Andrew T. Pavia. (2006) Antiviral Management of Seasonal and Pandemic Influenza. The Journal of Infectious Diseases 194:s2, S119-S126
CrossRef187
Andrew C. Singer, Miles A. Nunn, Ernest A. Gould, Andrew C. Johnson. (2006) Potential Risks Associated with the Proposed Widespread Use of Tamiflu. Environmental Health Perspectives 115:1, 102-106
CrossRef188
Aeron C Hurt, Hui-Ting Ho, Ian Barr. (2006) Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Review of Anti-infective Therapy 4:5, 795-805
CrossRef189
Alan W Hampson. (2006) Avian influenza: A pandemic waiting in the wings?. Emergency Medicine Australasia 18:5-6, 420-429
CrossRef190
Gabriele Neumann, Yoshihiro Kawaoka. 2006. Influenza Epidemics. .
CrossRef191
Rupert J. Russell, Lesley F. Haire, David J. Stevens, Patrick J. Collins, Yi Pu Lin, G. Michael Blackburn, Alan J. Hay, Steven J. Gamblin, John J. Skehel. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:7107, 45-49
CrossRef192
Jenny Bryan. (2006) Combating viral resistance to treatment: VIRGIL after two successful years. Future Virology 1:5, 567-571
CrossRef193
Kenneth W. Tsang, Young-Soo Shim, Thomas K. S. Wong, C. K. Liam, Philip Eng, W. K. Lam, W. H. Seto. (2006) Possible case scenarios and logistic issues in H5N1 pandemic. Respirology 11:5, 520-522
CrossRef194
Frederick G. Hayden. (2006) Antivirals for influenza: Historical perspectives and lessons learned. Antiviral Research 71:2-3, 372-378
CrossRef195
Richard J. Scarfone, Sharon Alexander, Susan E. Coffin, Keith H. St. John, Frank Sullivan, Jacqueline Wagner, Theoklis Zaoutis. (2006) Emergency Preparedness for Pandemic Influenza. Pediatric Emergency Care 22:9, 661-668
CrossRef196
Hitoshi Oshitani. (2006) Potential benefits and limitations of various strategies to mitigate the impact of an influenza pandemic. Journal of Infection and Chemotherapy 12:4, 167-171
CrossRef197
Tom Jefferson, Mark A Jones, Peter Doshi, Chris B Del Mar, Liz Dooley, Rokuro Hama, Carl J Heneghan, Tom Jefferson. 2006. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. .
CrossRef198
David S. Fedson. (2006) Pandemic Influenza: A Potential Role for Statins in Treatment and Prophylaxis. Clinical Infectious Diseases 43:2, 199-205
CrossRef199
Matthew K. Wynia*. (2006) Markets and Public Health: Pushing and Pulling Vaccines into Production. The American Journal of Bioethics 6:3, 3-6
CrossRef200
D. Kumar, A. Humar. (2006) Pandemic Influenza and Its Implications for Transplantation.. American Journal of Transplantation 6:7, 1512-1517
CrossRef201
Pascale C. Gruber, Charles D. Gomersall, Gavin M. Joynt. (2006) Avian influenza (H5N1): implications for intensive care. Intensive Care Medicine 32:6, 823-829
CrossRef202
Magda Campins Martí, Javier Díez Domingo. (2006) Gripe aviar: ¿para cuándo la vacuna?. Medicina Clínica 127:3, 93-95
CrossRef203
Adnan Mushtaq, Mohamed El-Azizi, Nancy Khardori. (2006) Category C Potential Bioterrorism Agents and Emerging Pathogens. Infectious Disease Clinics of North America 20:2, 423-441
CrossRef204
Peter C Doherty, Stephen J Turner, Richard G Webby, Paul G Thomas. (2006) Influenza and the challenge for immunology. Nature Immunology 7:5, 449-455
CrossRef205
P. L. L. Bruijnzeel. (2006) Oseltamivir-resistentie gedurende behandeling van influenza (H5N1) infectie. MFM 44:4, 114-115
CrossRef206
Frederick G Hayden. (2006) Respiratory viral threats. Current Opinion in Infectious Diseases 19:2, 169-178
CrossRef207
L. A. M. Elders, M. Y. H. Hie, A. Burdorf. (2006) Effectmeting gebruik neuraminidaseremmer bij steigerbouwers die verzuimen vanwege griep. Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde 14:4, 215-219
CrossRef208
Kennedy F Shortridge. (2006) Influenza pandemic preparedness: gauging from EU plans. The Lancet 367:9520, 1374-1375
CrossRef209
(2006) Oseltamivir Resistance in Influenza A (H5N1) Infection. New England Journal of Medicine 354:13, 1423-1424
Full Text210
Treanor, John J., Campbell, James D., Zangwill, Kenneth M., Rowe, Thomas, Wolff, Mark, . (2006) Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine. New England Journal of Medicine 354:13, 1343-1351
Full Text211
Poland, Gregory A., . (2006) Vaccines against Avian Influenza — A Race against Time. New England Journal of Medicine 354:13, 1411-1413
Full Text212
Stephen M Ford, John D Grabenstein. (2006) Pandemics, Avian Influenza A (H5N1), and a Strategy for Pharmacists. Pharmacotherapy 26:3, 312-322
CrossRef213
Jan-Inge Henter, Chun-Bong Chow, Chi-Wai Leung, Yu-Lung Lau. (2006) Cytotoxic therapy for severe avian influenza A (H5N1) infection. The Lancet 367:9513, 870-873
CrossRef214
PD Griffiths. (2006) Influenza: conundrums from cadavers. Reviews in Medical Virology 16:2, 67-68
CrossRef215
James C. Pile, Steven M. Gordon. (2006) Pandemic influenza and the hospitalist: Apocalypse when?. Journal of Hospital Medicine 1:2, 118-123
CrossRef216
Hayden, Frederick G., . (2006) Antiviral Resistance in Influenza Viruses — Implications for Management and Pandemic Response. New England Journal of Medicine 354:8, 785-788
Full Text217
Peter Palese, Terrence M. Tumpey, Adolfo Garcia-Sastre. (2006) What Can We Learn from Reconstructing the Extinct 1918 Pandemic Influenza Virus?. Immunity 24:2, 121-124
CrossRef218
David L. Heymann. (2006) Resistance to Anti-Infective Drugs and the Threat to Public Health. Cell 124:4, 671-675
CrossRef219
José Luis Viejo Bañuelos. (2006) Manifestaciones respiratorias de la gripe aviar. Archivos de Bronconeumología 42, 12-18
CrossRef220
T Jefferson, V Demicheli, D Rivetti, M Jones, C Di Pietrantonj, A Rivetti. (2006) Antivirals for influenza in healthy adults: systematic review. The Lancet 367:9507, 303-313
CrossRef221
Howard Friel, Harvey Lederman. (2006) A nutritional supplement formula for influenza A (H5N1) infection in humans. Medical Hypotheses 67:3, 578-587
CrossRef222
Christina E. Mills, James M. Robins, Carl T. Bergstrom, Marc Lipsitch. (2006) Pandemic Influenza: Risk of Multiple Introductions and the Need to Prepare for Them. PLoS Medicine 3:6, e135
CrossRef223
Hurng-Chun Lee, Jean Salzemann, Nicolas Jacq, Hsin-Yen Chen, Li-Yung Ho, Ivan Merelli, Luciano Milanesi, Vincent Breton, Simon C. Lin, Ying-Ta Wu. (2006) Grid-Enabled High-Throughput <emphasis emphasistype="italic">In Silico</emphasis> Screening Against Influenza A Neuraminidase. IEEE Transactions on Nanobioscience 5:4, 288-295
CrossRef224
Moscona, Anne, . (2005) Oseltamivir Resistance — Disabling Our Influenza Defenses. New England Journal of Medicine 353:25, 2633-2636
Full Text
- Letters
